Last reviewed · How we verify
trivalent seasonal influenza vaccine
trivalent seasonal influenza vaccine is a inactivated influenza vaccine Biologic drug developed by Sinovac Biotech Co., Ltd. It is currently FDA-approved for Prevention of seasonal influenza in adults and children. Also known as: Anflu®, IVACFLU-S.
This vaccine stimulates the immune system to produce antibodies and cellular immunity against three strains of seasonal influenza virus.
This vaccine stimulates the immune system to produce antibodies and cellular immunity against three strains of seasonal influenza virus. Used for Prevention of seasonal influenza in adults and children.
At a glance
| Generic name | trivalent seasonal influenza vaccine |
|---|---|
| Also known as | Anflu®, IVACFLU-S |
| Sponsor | Sinovac Biotech Co., Ltd |
| Drug class | inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The trivalent seasonal influenza vaccine contains inactivated viral antigens from three influenza strains (typically two A subtypes and one B type) that are selected annually based on epidemiological predictions. Upon administration, these antigens trigger both humoral (antibody-mediated) and cellular immune responses, enabling the body to recognize and neutralize circulating influenza viruses before infection or reduce disease severity if infection occurs.
Approved indications
- Prevention of seasonal influenza in adults and children
Common side effects
- Injection site soreness or erythema
- Myalgia
- Headache
- Low-grade fever
- Fatigue
Key clinical trials
- Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine (PHASE1, PHASE2)
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (PHASE3)
- Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older (PHASE3)
- Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (PHASE3)
- A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision (EARLY_PHASE1)
- Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived) (PHASE3)
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age (PHASE3)
- Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- trivalent seasonal influenza vaccine CI brief — competitive landscape report
- trivalent seasonal influenza vaccine updates RSS · CI watch RSS
- Sinovac Biotech Co., Ltd portfolio CI
Frequently asked questions about trivalent seasonal influenza vaccine
What is trivalent seasonal influenza vaccine?
How does trivalent seasonal influenza vaccine work?
What is trivalent seasonal influenza vaccine used for?
Who makes trivalent seasonal influenza vaccine?
Is trivalent seasonal influenza vaccine also known as anything else?
What drug class is trivalent seasonal influenza vaccine in?
What development phase is trivalent seasonal influenza vaccine in?
What are the side effects of trivalent seasonal influenza vaccine?
Related
- Drug class: All inactivated influenza vaccine drugs
- Manufacturer: Sinovac Biotech Co., Ltd — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Prevention of seasonal influenza in adults and children
- Also known as: Anflu®, IVACFLU-S
- Compare: trivalent seasonal influenza vaccine vs similar drugs
- Pricing: trivalent seasonal influenza vaccine cost, discount & access